Skip to main content
SpringerLink
Log in
Book cover

Experimental and Applied Immunotherapy pp 251–278Cite as

Genetically Engineered Antigen Specificity in T Cells for Adoptive Immunotherapy

  • Chapter
  • First Online:

  • 849 Accesses

Abstract

Antigen specificity has been genetically conferred to human T cells for therapy through the transfer of sequences encoding antigen-specific T-cell receptors (TCRs) or through the antigen-specific antibody-based chimeric antigen receptors (CARs). By either method, the advantage of the adoptive transfer of modified T cells over immunotherapies developed to date such as vaccines or cytokines alone is that T cells have the ability to directly traffic to the site of tumor or infection, to multiply at that site, and to persist in a memory state for months to years.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Billingham, R. E., L. Brent, and P. B. Medawar. 1954. Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity. Proc R Soc Lond B Biol Sci 143:58.

    Article  PubMed  CAS  Google Scholar 

  2. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, M. R. Robinson, M. Raffeld, P. Duray, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, S. A. Mavroukakis, D. E. White, and S. A. Rosenberg. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850.

    Article  PubMed  CAS  Google Scholar 

  3. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, L. J. Rogers, G. J. Gracia, S. A. Jones, D. P. Mangiameli, M. M. Pelletier, J. Gea-Banacloche, M. R. Robinson, D. M. Berman, A. C. Filie, A. Abati, and S. A. Rosenberg. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23:2346.

    Article  PubMed  CAS  Google Scholar 

  4. Dembic, Z., W. Haas, S. Weiss, J. McCubrey, H. Kiefer, H. von Boehmer, and M. Steinmetz. 1986. Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature 320:232.

    Article  PubMed  CAS  Google Scholar 

  5. Gabert, J., C. Langlet, R. Zamoyska, J. R. Parnes, A. M. Schmitt-Verhulst, and B. Malissen. 1987. Reconstitution of MHC class I specificity by transfer of the T cell receptor and Lyt-2 genes. Cell 50:545.

    Article  PubMed  CAS  Google Scholar 

  6. Saito, T., A. Weiss, J. Miller, M. A. Norcross, and R. N. Germain. 1987. Specific antigen-Ia activation of transfected human T cells expressing murine Ti alpha beta-human T3 receptor complexes. Nature 325:125.

    Article  PubMed  CAS  Google Scholar 

  7. Rosenberg, S. A., P. Aebersold, K. Cornetta, A. Kasid, R. A. Morgan, R. Moen, E. M. Karson, M. T. Lotze, J. C. Yang, S. L. Topalian, and. 1990. Gene transfer into humans– immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323:570.

    Article  PubMed  CAS  Google Scholar 

  8. Cooper, L. J., M. S. Topp, C. Pinzon, I. Plavec, M. C. Jensen, S. R. Riddell, and P. D. Greenberg. 2004. Enhanced transgene expression in quiescent and activated human CD8+ T cells. Hum. Gene Ther. 15:648.

    Article  PubMed  CAS  Google Scholar 

  9. Sauce, D., M. Bodinier, M. Garin, B. Petracca, N. Tonnelier, A. Duperrier, J. V. Melo, J. F. Apperley, C. Ferrand, P. Herve, F. Lang, P. Tiberghien, and E. Robinet. 2002. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood 99:1165.

    Article  PubMed  CAS  Google Scholar 

  10. Ellis, J. 2005. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum. Gene Ther. 16:1241.

    Article  PubMed  CAS  Google Scholar 

  11. Pfeifer, A., M. Ikawa, Y. Dayn, and I. M. Verma. 2002. Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc. Natl. Acad. Sci. USA 99:2140.

    Article  PubMed  CAS  Google Scholar 

  12. Montini, E., D. Cesana, M. Schmidt, F. Sanvito, M. Ponzoni, C. Bartholomae, S. L. Sergi, F. Benedicenti, A. Ambrosi, S. C. Di, C. Doglioni, K. C. von, and L. Naldini. 2006. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24:687.

    Article  PubMed  CAS  Google Scholar 

  13. Mitchell, R. S., B. F. Beitzel, A. R. Schroder, P. Shinn, H. Chen, C. C. Berry, J. R. Ecker, and F. D. Bushman. 2004. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS. Biol. 2:E234.

    Article  PubMed  CAS  Google Scholar 

  14. Hacein-Bey-Abina, S., C. von Kalle, M. Schmidt, F. Le Deist, N. Wulffraat, E. McIntyre, I. Radford, J. L. Villeval, C. C. Fraser, M. Cavazzana-Calvo, and A. Fischer. 2003. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348:255.

    Article  PubMed  Google Scholar 

  15. Hacein-Bey-Abina, S., C. von Kalle, M. Schmidt, M. P. McCcormack, N. Wulffraat, P. Leboulch, A. Lim, C. S. Osborne, R. Pawliuk, E. Morillon, R. Sorensen, A. Forster, P. Fraser, J. I. Cohen, G. de Saint Basile, I. Alexander, U. Wintergerst, T. Frebourg, A. Aurias, D. Stoppa-Lyonnet, S. Romana, I. Radford-Weiss, F. Gross, F. Valensi, E. Delabesse, E. Macintyre, F. Sigaux, J. Soulier, L. E. Leiva, M. Wissler, C. Prinz, T. H. Rabbitts, F. Le Deist, A. Fischer, and M. Cavazzana-Calvo. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415.

    Article  PubMed  CAS  Google Scholar 

  16. Gaspar, H. B., K. L. Parsley, S. Howe, D. King, K. C. Gilmour, J. Sinclair, G. Brouns, M. Schmidt, K. C. von, T. Barington, M. A. Jakobsen, H. O. Christensen, G. A. Al, H. N. White, J. L. Smith, R. J. Levinsky, R. R. Ali, C. Kinnon, and A. J. Thrasher. 2004. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 364:2181.

    Article  PubMed  CAS  Google Scholar 

  17. Howe, S. J., M. R. Mansour, K. Schwarzwaelder, C. Bartholomae, M. Hubank, H. Kempski, M. H. Brugman, K. Pike-Overzet, S. J. Chatters, R. D. de, K. C. Gilmour, S. Adams, S. I. Thornhill, K. L. Parsley, F. J. Staal, R. E. Gale, D. C. Linch, J. Bayford, L. Brown, M. Quaye, C. Kinnon, P. Ancliff, D. K. Webb, M. Schmidt, K. C. von, H. B. Gaspar, and A. J. Thrasher. 2008. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118:3143.

    Article  PubMed  CAS  Google Scholar 

  18. Naldini, L., U. Blomer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma, and D. Trono. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272:263.

    Article  PubMed  CAS  Google Scholar 

  19. Sinn, P. L., S. L. Sauter, and P. B. McCray, Jr. 2005. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors – design, biosafety, and production. Gene Ther. 12:1089.

    Article  PubMed  CAS  Google Scholar 

  20. Verhoeyen, E., V. Dardalhon, O. Ducrey-Rundquist, D. Trono, N. Taylor, and F. L. Cosset. 2003. IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood. 101:2167.

    Article  PubMed  CAS  Google Scholar 

  21. Humeau, L. M., G. K. Binder, X. Lu, V. Slepushkin, R. Merling, P. Echeagaray, M. Pereira, T. Slepushkina, S. Barnett, L. K. Dropulic, R. Carroll, B. L. Levine, C. H. June, and B. Dropulic. 2004. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol. Ther. 9:902.

    Article  PubMed  CAS  Google Scholar 

  22. Levine, B. L., L. M. Humeau, J. Boyer, R. R. MacGregor, T. Rebello, X. Lu, G. K. Binder, V. Slepushkin, F. Lemiale, J. R. Mascola, F. D. Bushman, B. Dropulic, and C. H. June. 2006. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. USA. 103:17372.

    Article  PubMed  CAS  Google Scholar 

  23. Wang, G. P., B. L. Levine, G. K. Binder, C. C. Berry, N. Malani, G. McGarrity, P. Tebas, C. H. June, and F. D. Bushman. 2009. Analysis of lentiviral vector integration in HIV + study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol. Ther. 17:844.

    Article  PubMed  CAS  Google Scholar 

  24. Varela-Rohena, A., P. E. Molloy, S. M. Dunn, Y. Li, M. M. Suhoski, R. G. Carroll, A. Milicic, T. Mahon, D. H. Sutton, B. Laugel, R. Moysey, B. J. Cameron, A. Vuidepot, M. A. Purbhoo, D. K. Cole, R. E. Phillips, C. H. June, B. K. Jakobsen, A. K. Sewell, and J. L. Riley. 2008. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat. Med. 14:1390.

    Article  PubMed  CAS  Google Scholar 

  25. Yang, S., C. J. Cohen, P. D. Peng, Y. Zhao, L. Cassard, Z. Yu, Z. Zheng, S. Jones, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan. 2008. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther. 15:1411.

    Article  PubMed  CAS  Google Scholar 

  26. Ferber, D. 2001. Gene therapy. Safer and virus-free? Science 294:1638.

    Article  PubMed  CAS  Google Scholar 

  27. Zhao, Y., Z. Zheng, C. J. Cohen, L. Gattinoni, D. C. Palmer, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan. 2006. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol. Ther. 13:151.

    Article  PubMed  CAS  Google Scholar 

  28. Yoon, S. H., J. M. Lee, H. I. Cho, E. K. Kim, H. S. Kim, M. Y. Park, and T. G. Kim. 2009. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther. 16:489.

    Article  PubMed  CAS  Google Scholar 

  29. Robbins, P. F., M. E. Dudley, J. Wunderlich, M. El-Gamil, Y. F. Li, J. Zhou, J. Huang, D. J. Powell Jr., and S. A. Rosenberg. 2004. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173:7125.

    PubMed  CAS  Google Scholar 

  30. Johnson, L. A., B. Heemskerk, D. J. Powell, Jr., C. J. Cohen, R. A. Morgan, M. E. Dudley, P. F. Robbins, and S. A. Rosenberg. 2006. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol. 177:6548.

    PubMed  CAS  Google Scholar 

  31. Li, Y., R. Moysey, P. E. Molloy, A. L. Vuidepot, T. Mahon, E. Baston, S. Dunn, N. Liddy, J. Jacob, B. K. Jakobsen, and J. M. Boulter. 2005. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 23:349.

    Article  PubMed  CAS  Google Scholar 

  32. Dunn, S. M., P. J. Rizkallah, E. Baston, T. Mahon, B. Cameron, R. Moysey, F. Gao, M. Sami, J. Boulter, Y. Li, and B. K. Jakobsen. 2006. Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. Protein Sci. 15:710.

    Article  PubMed  CAS  Google Scholar 

  33. Zhao, Y., Z. Zheng, P. F. Robbins, H. T. Khong, S. A. Rosenberg, and R. A. Morgan. 2005. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol. 174:4415.

    PubMed  CAS  Google Scholar 

  34. Johnson, L. A., R. A. Morgan, M. E. Dudley, L. Cassard, J. C. Yang, M. S. Hughes, U. S. Kammula, R. E. Royal, R. M. Sherry, J. R. Wunderlich, C. C. Lee, N. P. Restifo, S. L. Schwarz, A. P. Cogdill, R. J. Bishop, H. Kim, C. C. Brewer, S. F. Rudy, C. Vanwaes, J. L. Davis, A. Mathur, R. T. Ripley, D. A. Nathan, C. M. Laurencot, and S. A. Rosenberg. 2009. Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 114:535.

    Article  PubMed  CAS  Google Scholar 

  35. Pogulis, R. J., M. J. Hansen, and L. R. Pease. 1998. Retroviral-mediated expression of an MHC class I-restricted T cell receptor in the CD8 T cell compartment of bone marrow-reconstituted mice. Hum. Gene Ther. 9:2285.

    Article  PubMed  CAS  Google Scholar 

  36. Pogulis, R. J., and L. R. Pease. 1998. A retroviral vector that directs simultaneous expression of alpha and beta T cell receptor genes. Hum. Gene Ther. 9:2299.

    Article  PubMed  CAS  Google Scholar 

  37. Clay, T. M., M. C. Custer, J. Sachs, P. Hwu, S. A. Rosenberg, and M. I. Nishimura. 1999. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163:507.

    PubMed  CAS  Google Scholar 

  38. Pittet, M. J., V. Rubio-Godoy, G. Bioley, P. Guillaume, P. Batard, D. Speiser, I. Luescher, J. C. Cerottini, P. Romero, and A. Zippelius. 2003. Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J. Immunol. 171:1844.

    PubMed  CAS  Google Scholar 

  39. Robbins, P. F., Y. F. Li, M. El-Gamil, Y. Zhao, J. A. Wargo, Z. Zheng, H. Xu, R. A. Morgan, S. A. Feldman, L. A. Johnson, A. D. Bennett, S. M. Dunn, T. M. Mahon, B. K. Jakobsen, and S. A. Rosenberg. 2008. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180:6116.

    PubMed  CAS  Google Scholar 

  40. Stanislawski, T., R. H. Voss, C. Lotz, E. Sadovnikova, R. A. Willemsen, J. Kuball, T. Ruppert, R. L. Bolhuis, C. J. Melief, C. Huber, H. J. Stauss, and M. Theobald. 2001. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2:962.

    Article  PubMed  CAS  Google Scholar 

  41. Holler, P. D., P. O. Holman, E. V. Shusta, S. O’Herrin, K. D. Wittrup, and D. M. Kranz. 2000. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl. Acad. Sci. USA. 97:5387.

    Article  PubMed  CAS  Google Scholar 

  42. Cohen, C. J., Z. Zheng, R. Bray, Y. Zhao, L. A. Sherman, S. A. Rosenberg, and R. A. Morgan. 2005. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J. Immunol. 175:5799.

    PubMed  CAS  Google Scholar 

  43. Kuball, J., F. W. Schmitz, R. H. Voss, E. A. Ferreira, R. Engel, P. Guillaume, S. Strand, P. Romero, C. Huber, L. A. Sherman, and M. Theobald. 2005. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity. 22:117.

    Article  PubMed  CAS  Google Scholar 

  44. Berger, C., C. A. Blau, M. L. Huang, J. D. Iuliucci, D. C. Dalgarno, J. Gaschet, S. Heimfeld, T. Clackson, and S. R. Riddell. 2004. Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood. 103:1261.

    Article  PubMed  CAS  Google Scholar 

  45. Kershaw, M. H., J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. Mavroukakis, D. E. White, J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, C. C. Chen, J. C. Yang, S. A. Rosenberg, and P. Hwu. 2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12:6106.

    Article  PubMed  CAS  Google Scholar 

  46. Lamers, C. H., S. C. Langeveld, C. M. Groot-van Ruijven, R. Debets, S. Sleijfer, and J. W. Gratama. 2007. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol. Immunother. 56:1875.

    Article  PubMed  Google Scholar 

  47. Park, J. R., D. L. DiGiusto, M. Slovak, C. Wright, A. Naranjo, J. Wagner, H. B. Meechoovet, C. Bautista, W. C. Chang, J. R. Ostberg, and M. C. Jensen. 2007. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15:825.

    PubMed  CAS  Google Scholar 

  48. Shultz, L. D., F. Ishikawa, and D. L. Greiner. 2007. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7:118.

    Article  PubMed  CAS  Google Scholar 

  49. Clark, R. A., K. Yamanaka, M. Bai, R. Dowgiert, and T. S. Kupper. 2005. Human skin cells support thymus-independent T cell development. J. Clin. Invest. 115:3239.

    Article  PubMed  CAS  Google Scholar 

  50. Schmitt, T. M., R. F. de Pooter, M. A. Gronski, S. K. Cho, P. S. Ohashi, and J. C. Zuniga-Pflucker. 2004. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat. Immunol. 5:410.

    Article  PubMed  CAS  Google Scholar 

  51. Schlissel, M. S. 2003. Regulating antigen-receptor gene assembly. Nat. Rev. Immunol. 3:890.

    Article  PubMed  CAS  Google Scholar 

  52. van der Veken, V., R. S. Hagedoorn, M. M. van Loenen, R. Willemze, J. H. Falkenburg, and M. H. Heemskerk. 2006. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity. Cancer Res. 66:3331.

    Article  PubMed  CAS  Google Scholar 

  53. Heemskerk, M. H., R. S. Hagedoorn, M. A. van der Hoorn, d. van, V, M. Hoogeboom, M. G. Kester, R. Willemze, and J. H. Falkenburg. 2007. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood. 109:235.

    Article  PubMed  CAS  Google Scholar 

  54. Willemsen, R. A., M. E. Weijtens, C. Ronteltap, Z. Eshhar, J. W. Gratama, P. Chames, and R. L. Bolhuis. 2000. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther. 7:1369.

    Article  PubMed  CAS  Google Scholar 

  55. Kuball, J., M. L. Dossett, M. Wolfl, W. Y. Ho, R. H. Voss, C. Fowler, and P. D. Greenberg. 2007. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood. 109:2331.

    Article  PubMed  CAS  Google Scholar 

  56. Voss, R. H., J. Kuball, R. Engel, P. Guillaume, P. Romero, C. Huber, and M. Theobald. 2006. Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen- specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression. Immunol. Res. 34:67.

    Article  PubMed  CAS  Google Scholar 

  57. Greenberg, P. D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281–355.

    Article  PubMed  CAS  Google Scholar 

  58. Cohen, C. J., Y. F. Li, M. El-Gamil, P. F. Robbins, S. A. Rosenberg, and R. A. Morgan. 2007. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67:3898.

    Article  PubMed  CAS  Google Scholar 

  59. Sebestyen, Z., E. Schooten, T. Sals, I. Zaldivar, J. E. San, B. Alarcon, S. Bobisse, A. Rosato, J. Szollosi, J. W. Gratama, R. A. Willemsen, and R. Debets. 2008. Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer. J. Immunol. 180:7736.

    PubMed  CAS  Google Scholar 

  60. Hughes, M. S., Y. Y. Yu, M. E. Dudley, Z. Zheng, P. F. Robbins, Y. Li, J. Wunderlich, R. G. Hawley, M. Moayeri, S. A. Rosenberg, and R. A. Morgan. 2005. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene Ther. 16:457.

    Article  PubMed  CAS  Google Scholar 

  61. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, Z. Zheng, A. Nahvi, C. R. de Vries, L. J. Rogers-Freezer, S. A. Mavroukakis, and S. A. Rosenberg. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 314:126.

    Article  PubMed  CAS  Google Scholar 

  62. Pinthus, J. H., T. Waks, K. Kaufman-Francis, D. G. Schindler, A. Harmelin, H. Kanety, J. Ramon, and Z. Eshhar. 2003. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res. 63:2470.

    PubMed  CAS  Google Scholar 

  63. Gross, G., T. Waks, and Z. Eshhar. 1989. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. USA. 86:10024.

    Article  PubMed  CAS  Google Scholar 

  64. Mullaney, B. P., and M. G. Pallavicini. 2001. Protein-protein interactions in hematology and phage display. Exp. Hematol. 29:1136.

    Article  PubMed  CAS  Google Scholar 

  65. Eshhar, Z., T. Waks, G. Gross, and D. G. Schindler. 1993. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA. 90:720.

    Article  PubMed  CAS  Google Scholar 

  66. Carpenito, C., M. C. Milone, R. Hassan, J. C. Simonet, M. Lakhal, M. M. Suhoski, A. Varela-Rohena, K. M. Haines, D. F. Heitjan, S. M. Albelda, R. G. Carroll, J. L. Riley, I. Pastan, and C. H. June. 2009. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. USA. 106:3360.

    Article  PubMed  CAS  Google Scholar 

  67. Milone, M. C., J. D. Fish, C. Carpenito, R. G. Carroll, G. K. Binder, D. Teachey, M. Samanta, M. Lakhal, B. Gloss, G. net-Desnoyers, D. Campana, J. L. Riley, S. A. Grupp, and C. H. June. 2009. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T Cells and increased antileukemic efficacy in vivo. Mol. Ther. 17:1453.

    Article  PubMed  CAS  Google Scholar 

  68. Finney, H. M., A. D. Lawson, C. R. Bebbington, and A. N. Weir. 1998. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161:2791.

    PubMed  CAS  Google Scholar 

  69. Maher, J., R. J. Brentjens, G. Gunset, I. Riviere, and M. Sadelain. 2002. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat. Biotechnol. 20:70.

    Article  PubMed  CAS  Google Scholar 

  70. Friedmann-Morvinski, D., A. Bendavid, T. Waks, D. Schindler, and Z. Eshhar. 2005. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood. 105:3087.

    Article  PubMed  CAS  Google Scholar 

  71. Finney, H. M., A. N. Akbar, and A. D. Lawson. 2004. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J. Immunol. 172:104.

    PubMed  CAS  Google Scholar 

  72. Imai, C., K. Mihara, M. Andreansky, I. C. Nicholson, C. H. Pui, T. L. Geiger, and D. Campana. 2004. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 18:676.

    Article  PubMed  CAS  Google Scholar 

  73. Levine, B. L., W. B. Bernstein, M. Connors, N. Craighead, T. Lindsten, C. B. Thompson, and C. H. June. 1997. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J. Immunol. 159:5921.

    PubMed  CAS  Google Scholar 

  74. Paulos, C. M., M. M. Suhoski, G. Plesa, T. Jiang, S. Basu, T. N. Golovina, S. Jiang, N. A. Aqui, D. J. Powell, Jr., B. L. Levine, R. G. Carroll, J. L. Riley, and C. H. June. 2008. Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol. Res. 42:182.

    Article  PubMed  Google Scholar 

  75. Walker, R. E., C. M. Bechtel, V. Natarajan, M. Baseler, K. M. Hege, J. A. Metcalf, R. Stevens, A. Hazen, R. M. Blaese, C. C. Chen, S. F. Leitman, J. Palensky, J. Wittes, R. T. Davey, J. Falloon, M. A. Polis, J. A. Kovacs, D. F. Broad, B. L. Levine, M. R. Roberts, H. Masur, and H. C. Lane. 2000. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96:467.

    PubMed  CAS  Google Scholar 

  76. Mitsuyasu, R. T., P. A. Anton, S. G. Deeks, D. T. Scadden, E. Connick, M. T. Downs, A. Bakker, M. R. Roberts, C. H. June, S. Jalali, A. A. Lin, R. Pennathur-Das, and K. M. Hege. 2000. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 96:785.

    PubMed  CAS  Google Scholar 

  77. Riddell, S. R., M. Elliott, D. A. Lewinsohn, M. J. Gilbert, L. Wilson, S. A. Manley, S. D. Lupton, R. W. Overell, T. C. Reynolds, L. Corey, and P. D. Greenberg. 1996. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 2:216.

    Article  PubMed  CAS  Google Scholar 

  78. Lamers, C. H., S. Sleijfer, A. G. Vulto, W. H. Kruit, M. Kliffen, R. Debets, J. W. Gratama, G. Stoter, and E. Oosterwijk. 2006. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24:e20-e22.

    Article  PubMed  Google Scholar 

  79. Sadelain, M., I. Riviere, and R. Brentjens. 2003. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer. 3:35.

    Article  PubMed  CAS  Google Scholar 

  80. Freedman, A. S., A. W. Boyd, F. R. Bieber, J. Daley, K. Rosen, J. C. Horowitz, D. N. Levy, and L. M. Nadler. 1987. Normal cellular counterparts of B cell chronic lymphocytic leukemia. Blood. 70:418.

    PubMed  CAS  Google Scholar 

  81. Uckun, F. M., W. Jaszcz, J. L. Ambrus, A. S. Fauci, K. Gajl-Peczalska, C. W. Song, M. R. Wick, D. E. Myers, K. Waddick, and J. A. Ledbetter. 1988. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood. 71:13.

    PubMed  CAS  Google Scholar 

  82. Fearon, D. T., and M. C. Carroll. 2000. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu. Rev. Immunol. 18:393–422.

    Article  PubMed  CAS  Google Scholar 

  83. Scheuermann, R. H., and E. Racila. 1995. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk. Lymphoma. 18:385.

    Article  PubMed  CAS  Google Scholar 

  84. Schwonzen, M., C. Pohl, T. Steinmetz, W. Seckler, B. Vetten, J. Thiele, D. Wickramanayake, and V. Diehl. 1993. Immunophenotyping of low-grade B-cell lymphoma in blood and bone marrow: poor correlation between immunophenotype and cytological/histological classification. Br. J. Haematol. 83:232.

    Article  PubMed  CAS  Google Scholar 

  85. Li, Q., W. Hudson, D. Wang, E. Berven, F. M. Uckun, and J. H. Kersey. 1998. Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy. Cancer Immunol. Immunother. 47:121.

    Article  PubMed  CAS  Google Scholar 

  86. Ek, O., P. Gaynon, T. Zeren, L. M. Chelstrom, D. E. Myers, and F. M. Uckun. 1998. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase. Leuk. Lymphoma. 31:143.

    Article  PubMed  CAS  Google Scholar 

  87. Bejcek, B. E., D. Wang, E. Berven, C. A. Pennell, S. C. Peiper, S. Poppema, F. M. Uckun, and J. H. Kersey. 1995. Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen. Cancer Res. 55:2346.

    PubMed  CAS  Google Scholar 

  88. Nicholson, I. C., K. A. Lenton, D. J. Little, T. Decorso, F. T. Lee, A. M. Scott, H. Zola, and A. W. Hohmann. 1997. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol. Immunol. 34:1157.

    Article  PubMed  CAS  Google Scholar 

  89. Brentjens, R. J., J. B. Latouche, E. Santos, F. Marti, M. C. Gong, C. Lyddane, P. D. King, S. Larson, M. Weiss, I. Riviere, and M. Sadelain. 2003. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9:279.

    Article  PubMed  CAS  Google Scholar 

  90. Cooper, L. J., M. S. Topp, L. M. Serrano, S. Gonzalez, W. C. Chang, A. Naranjo, C. Wright, L. Popplewell, A. Raubitschek, S. J. Forman, and M. C. Jensen. 2003. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood. 101:1637.

    Article  PubMed  CAS  Google Scholar 

  91. Serrano, L. M., T. Pfeiffer, S. Olivares, T. Numbenjapon, J. Bennitt, D. Kim, D. Smith, G. McNamara, Z. Al-Kadhimi, J. Rosenthal, S. J. Forman, M. C. Jensen, and L. J. Cooper. 2006. Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood. 107:2643.

    Article  PubMed  CAS  Google Scholar 

  92. Cooper, L. J., Z. Al-Kadhimi, L. M. Serrano, T. Pfeiffer, S. Olivares, A. Castro, W. C. Chang, S. Gonzalez, D. Smith, S. J. Forman, and M. C. Jensen. 2005. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood. 105:1622.

    Article  PubMed  CAS  Google Scholar 

  93. Hollyman, D., J. Stefanski, M. Przybylowski, S. Bartido, O. Borquez-Ojeda, C. Taylor, R. Yeh, V. Capacio, M. Olszewska, J. Hosey, M. Sadelain, R. J. Brentjens, and I. Riviere. 2009. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J. Immunother. 32:169.

    Article  PubMed  CAS  Google Scholar 

  94. Till, B. G., M. C. Jensen, J. Wang, E. Y. Chen, B. L. Wood, H. A. Greisman, X. Qian, S. E. James, A. Raubitschek, S. J. Forman, A. K. Gopal, J. M. Pagel, C. G. Lindgren, P. D. Greenberg, S. R. Riddell, and O. W. Press. 2008. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 112:2261.

    Article  PubMed  CAS  Google Scholar 

  95. Westwood, J. A., M. J. Smyth, M. W. Teng, M. Moeller, J. A. Trapani, A. M. Scott, F. E. Smyth, G. A. Cartwright, B. E. Power, D. Honemann, H. M. Prince, P. K. Darcy, and M. H. Kershaw. 2005. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc. Natl. Acad. Sci. USA. 102:19051.

    Article  PubMed  CAS  Google Scholar 

  96. Parker, L. L., M. T. Do, J. A. Westwood, J. R. Wunderlich, M. E. Dudley, S. A. Rosenberg, and P. Hwu. 2000. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum. Gene Ther. 11:2377.

    Article  PubMed  CAS  Google Scholar 

  97. Hwu, P., J. C. Yang, R. Cowherd, J. Treisman, G. E. Shafer, Z. Eshhar, and S. A. Rosenberg. 1995. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 55:3369.

    PubMed  CAS  Google Scholar 

  98. Hwu, P., G. E. Shafer, J. Treisman, D. G. Schindler, G. Gross, R. Cowherd, S. A. Rosenberg, and Z. Eshhar. 1993. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J. Exp. Med. 178:361.

    Article  PubMed  CAS  Google Scholar 

  99. Chang, K., and I. Pastan. 1996. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. USA. 93:136.

    Article  PubMed  CAS  Google Scholar 

  100. Chang, K., L. H. Pai, J. K. Batra, I. Pastan, and M. C. Willingham. 1992. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res. 52:181.

    PubMed  CAS  Google Scholar 

  101. Scholler, N., N. Fu, Y. Yang, Z. Ye, G. E. Goodman, K. E. Hellstrom, and I. Hellstrom. 1999. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl. Acad. Sci. USA. 96:11531.

    Article  PubMed  CAS  Google Scholar 

  102. Badgwell, D., Z. Lu, L. Cole, H. Fritsche, E. N. Atkinson, E. Somers, J. Allard, R. G. Moore, K. H. Lu, and R. C. Bast Jr. 2007. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol. Oncol. 106:490.

    Article  PubMed  CAS  Google Scholar 

  103. Rump, A., Y. Morikawa, M. Tanaka, S. Minami, N. Umesaki, M. Takeuchi, and A. Miyajima. 2004. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem. 279:9190.

    Article  PubMed  CAS  Google Scholar 

  104. Gubbels, J. A., J. Belisle, M. Onda, C. Rancourt, M. Migneault, M. Ho, T. K. Bera, J. Connor, B. K. Sathyanarayana, B. Lee, I. Pastan, and M. S. Patankar. 2006. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol. Cancer. 5:50.

    Article  PubMed  CAS  Google Scholar 

  105. Ho, M., R. Hassan, J. ZHANG, Q. C. Wang, M. Onda, T. Bera, and I. Pastan. 2005. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin. Cancer Res. 11:3814.

    Article  PubMed  CAS  Google Scholar 

  106. Thomas, A. M., L. M. Santarsiero, E. R. Lutz, T. D. Armstrong, Y. C. Chen, L. Q. Huang, D. A. Laheru, M. Goggins, R. H. Hruban, and E. M. Jaffee. 2004. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. 200:297.

    Article  PubMed  CAS  Google Scholar 

  107. Yokokawa, J., C. Palena, P. Arlen, R. Hassan, M. Ho, I. Pastan, J. Schlom, and K. Y. Tsang. 2005. Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin. Cancer Res. 11:6342.

    Article  PubMed  CAS  Google Scholar 

  108. Breidenbach, M., D. T. Rein, M. Everts, J. N. Glasgow, M. Wang, M. J. Passineau, R. D. Alvarez, N. Korokhov, and D. T. Curiel. 2005. Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther. 12:187.

    Article  PubMed  CAS  Google Scholar 

  109. Hassan, R., and M. Ho. 2008. Mesothelin targeted cancer immunotherapy. Eur. J. Cancer. 44:46.

    Article  PubMed  CAS  Google Scholar 

  110. Hassan, R., W. Ebel, E. L. Routhier, R. Patel, J. B. Kline, J. ZHANG, Q. Chao, S. Jacob, H. Turchin, L. Gibbs, M. D. Phillips, S. Mudali, C. Iacobuzio-Donahue, E. M. Jaffee, M. Moreno, I. Pastan, P. M. Sass, N. C. Nicolaides, and L. Grasso. 2007. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 7:20.

    PubMed  Google Scholar 

  111. Chang, C. L., T. C. Wu, and C. F. Hung. 2007. Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther. 14:1189.

    Article  PubMed  CAS  Google Scholar 

  112. Hung, C. F., Y. C. Tsai, L. He, and T. C. Wu. 2007. Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther. 14:921.

    Article  PubMed  CAS  Google Scholar 

  113. Powell, D. J., Jr., M. E. Dudley, K. A. Hogan, J. R. Wunderlich, and S. A. Rosenberg. 2006. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J. Immunol. 177:6527.

    PubMed  CAS  Google Scholar 

  114. Rapoport, A. P., E. A. Stadtmauer, N. Aqui, A. Badros, J. Cotte, L. Chrisley, E. Veloso, Z. Zheng, S. Westphal, R. Mair, N. Chi, B. Ratterree, M. F. Pochran, S. Natt, J. Hinkle, C. Sickles, A. Sohal, K. Ruehle, C. Lynch, L. Zhang, D. L. Porter, S. Luger, C. Guo, H. B. Fang, W. Blackwelder, K. Hankey, D. Mann, R. Edelman, C. Frasch, B. L. Levine, A. Cross, and C. H. June. 2005. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11:1230.

    Article  PubMed  CAS  Google Scholar 

  115. Cavazzana-Calvo, M., S. Hacein-Bey, B. de Saint, F. Gross, E. Yvon, P. Nusbaum, F. Selz, C. Hue, S. Certain, J. L. Casanova, P. Bousso, F. L. Deist, and A. Fischer. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669.

    Article  PubMed  CAS  Google Scholar 

  116. Thrasher, A. J., H. B. Gaspar, C. Baum, U. Modlich, A. Schambach, F. Candotti, M. Otsu, B. Sorrentino, L. Scobie, E. Cameron, K. Blyth, J. Neil, S. H. Abina, M. Cavazzana-Calvo, and A. Fischer. 2006. Gene therapy: X-SCID transgene leukaemogenicity. Nature. 443:E5-E6.

    Article  CAS  Google Scholar 

  117. Hacein-Bey-Abina, S., C. von Kalle, M. Schmidt, M. P. McCormack, N. Wulffraat, P. Leboulch, A. Lim, C. S. Osborne, R. Pawliuk, E. Morillon, R. Sorensen, A. Forster, P. Fraser, J. I. Cohen, B. G. de Saint, I. Alexander, U. Wintergerst, T. Frebourg, A. Aurias, D. Stoppa-Lyonnet, S. Romana, I. Radford-Weiss, F. Gross, F. Valensi, E. Delabesse, E. Macintyre, F. Sigaux, J. Soulier, L. E. Leiva, M. Wissler, C. Prinz, T. H. Rabbitts, F. Le Deist, A. Fischer, and M. Cavazzana-Calvo. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415.

    Article  PubMed  CAS  Google Scholar 

  118. Hacein-Bey-Abina, S., K. C. von, M. Schmidt, D. F. Le, N. Wulffraat, E. McIntyre, I. Radford, J. L. Villeval, C. C. Fraser, M. Cavazzana-Calvo, and A. Fischer. 2003. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348:255.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge helpful discussions and assistance from Dr. Carl June, Dr. James Riley, Dr. Richard Carroll, Dr. Anne Chew, Dr. Gwendolyn Binder, and Dr. Yangbing Zhao.

Author information

Authors and Affiliations

  1. Pathology and Laboratory Medicine, Clinical Cell and Vaccine Production Facility, Ovarian Cancer Research Center, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA

    Daniel J. Powell Jr

Authors
  1. Daniel J. Powell Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruce L. Levine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel J. Powell Jr .

Editor information

Editors and Affiliations

  1. University Health Network, University of Toronto, College Street 67, Toronto, M5G 2M1, Ontario, Canada

    Jeffrey Medin

  2. National Cancer Institute, Experimental Transplatation &, National Institutes of Health, Center Drive 10, Bethesda, 20892, Maryland, USA

    Daniel Fowler

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Powell, D.J., Levine, B.L. (2011). Genetically Engineered Antigen Specificity in T Cells for Adoptive Immunotherapy. In: Medin, J., Fowler, D. (eds) Experimental and Applied Immunotherapy. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-980-2_12

Download citation

Publish with us

Policies and ethics

Search

Navigation